-
1 Comment
Phio Pharmaceuticals Corp is currently in a long term downtrend where the price is trading 21.7% below its 200 day moving average.
From a valuation standpoint, the stock is 96.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 48.0.
Phio Pharmaceuticals Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 100.0% to $0 since the same quarter in the previous year.
Finally, its free cash flow fell by 2.9% to $-3M since the same quarter in the previous year.
Based on the above factors, Phio Pharmaceuticals Corp gets an overall score of 2/5.
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| ISIN | US71880W5013 |
| Market Cap | 8M |
|---|---|
| PE Ratio | None |
| Beta | 0.98 |
| Target Price | 4 |
| Dividend Yield | None |
Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PHIO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
